

MINISTRY OF HEALTH PHARMACY AND POISONS BOARD

NOTICE ON PRESCRIPTION ERRORS INVOLVING ACECLOFENAC-COMBINATION MEDICATIONS (01/2024).

The Pharmacy and Poisons Board (the Board) is mandated under the Pharmacy and Poisons Act (CAP 244) to ensure patient safety by evaluating safety reports submitted to the pharmacovigilance department. The Board conducts routine quarterly analyses of individual case safety reports (ICSRs) submitted to the National Pharmacovigilance Centre (NPC).

During the routine quarterly pharmacovigilance summary, the Board has observed increasing reports of prescription errors involving aceclofenac-combination medications. These medications are widely used for their anti-inflammatory and pain-relieving properties, but errors in their prescription or administration can lead to serious health risks.

The most common errors are prescription errors, particularly overdosing, where the prescribing instructions result in more than the recommended maximum daily dose of 200 mg. These errors are likely to expose patients to the risk of gastrointestinal bleeding, ulceration, and perforation.

The Board recommends healthcare professionals to ensure the correct medication and dosage are prescribed, inform patients about the correct usage and potential side effects, obtain comprehensive patient history and consider patient's medical history to avoid contraindications. Conversely, patients are to be advised to adhere strictly to the prescribed dosage and administration guidelines and immediately contact healthcare providers if any adverse effects are experienced.

For more information, you may contact us at 0795 743 040 or through email to pv@ppb.go.ke.

Any suspected adverse events or quality defects on health products and technologies should be reported to;

- https://pv.pharmacyboardkenya.org/
- Mobile application: mPvERS both on Android & iOS
- USSD *271# by the General Public/Patients

CHIEF EXECUTIVE OFFICER

30th SEPTEMBER 2024